{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:32:10Z","timestamp":1759991530073,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.anai.2024.04.020","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T07:10:41Z","timestamp":1719817841000},"page":"18-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0088-5262","authenticated-orcid":false,"given":"Timothy M.","family":"Buckey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anai.2024.04.020_bib0001","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2024.04.020_bib0002","unstructured":"U.S. Food and Drug Administration. FDA approves first medication to help reduce allergic reactions to multiple foods after accidental exposure. Accessed February 28, 2024. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental"},{"issue":"5","key":"10.1016\/j.anai.2024.04.020_bib0003","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaip.2024.02.018","article-title":"An ethical framework for allergy and immunology","volume":"12","author":"Buckey","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2024.04.020_bib0004","unstructured":"UpToDate. Omalizumab: drug information. Accessed March 26, 2024. Available at: https:\/\/www.uptodate.com\/contents\/omalizumab-drug-information?search=omalizumab&source=panel_search_result&selectedTitle=1\u223c101&usage_type=panel&kp_tab=drug_general&display_rank=1"},{"key":"10.1016\/j.anai.2024.04.020_bib0005","unstructured":"GoodRx. How much is an EpiPen? Learn about the costs and 4 ways to save. Accessed February 28, 2024. Available at: https:\/\/www.goodrx.com\/epinephrine-epipen\/how-to-save-cost"},{"issue":"21","key":"10.1016\/j.anai.2024.04.020_bib0006","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMp2113323","article-title":"Drug-pricing debate redux \u2014 should cost-effectiveness analysis be used now to price pharmaceuticals?","volume":"385","author":"Neumann","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2024.04.020_bib0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000509119","article-title":"Principles of clinical ethics and their application to practice","volume":"30","author":"Varkey","year":"2021","journal-title":"Med Princ Pract"},{"issue":"9661","key":"10.1016\/j.anai.2024.04.020_bib0008","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(09)60137-9","article-title":"Principles for allocation of scarce medical interventions","volume":"373","author":"Persad","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2024.04.020_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaip.2021.10.008","article-title":"Fatal food anaphylaxis: distinguishing fact from fiction","volume":"10","author":"Anagnostou","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.04.020_bib0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1257\/pol.20150523","article-title":"Do physicians respond to the costs and cost-sensitivity of their patients?","volume":"10","author":"Carrera","year":"2018","journal-title":"Am Econ J Econ Policy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T21:17:39Z","timestamp":1731964659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1081120624002400"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.04.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}